search

Active clinical trials for "Seizures"

Results 361-370 of 775

A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial...

EpilepsiesPartial

This study is planned to evaluate the safety and efficacy of L059 (levetiracetam) in long-term administration in patients who completed N01020 [NCT00160165] or N01221 [NCT00280696].

Completed2 enrollment criteria

4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory...

Epilepsy

The purpose of this study is to determine the safety of perampanel given as adjunctive, long-term treatment in patients with refractory partial onset seizures.

Completed13 enrollment criteria

A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures

EpilepsyPartial

A 12-week Evaluation Period will be used to characterize potential cognitive and neuropsychological effects of LEV (20 - 60 mg/kg/day), as adjunctive treatment in children 4 - 16 years old, inclusive, with refractory partial onset seizures when compared to adjunctive treatment with placebo.

Completed8 enrollment criteria

LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures

SeizureAbsence

This is an open-label study evaluating the efficacy and safety of lamotrigine (LTG) for the treatment of newly-diagnosed typical absence seizures. Subjects will be children and adolescents < 13 years of age. It will be conducted at multiple sites in the US. The study will consist of 4 phases: Screen Phase (up to 1 week), Baseline Phase (24 hours), Escalation Phase (up to 20 weeks) and Maintenance Phase (12 weeks). Subjects will receive increasing doses of LTG according to the dosing schedule until attaining seizure freedom as confirmed by hyperventilation (HV) for clinical signs and a 1-hr EEG at 2 consecutive weekly visits. At that point, subjects will move into the 12-week Maintenance Phase. Subjects who do not achieve seizure freedom upon reaching the maximum dose (10.2mg/kg/day) with the specified dose escalation will be discontinued from the study. During the Maintenance Phase, the investigators will use their best effort to maintain the subjects at the efficacious dose reached. If the subjects have unacceptable side effects or inadequate seizure control, the doses of study drug can be increased or decreased as specified in the dosing schedule. Safety will be assessed by monitoring adverse events, laboratory assessments, and serum lamotrigine levels. Health outcomes assessments will also be conducted.

Completed16 enrollment criteria

Clobazam in Subjects With Lennox-Gastaut Syndrome

EpilepsyEpilepsy2 more

The purpose of this study is to evaluate the safety and efficacy of clobazam as adjunctive therapy in the treatment of seizures which lead to drop attacks (drop seizures) in subjects 2 to 30 years of age with Lennox-Gastaut Syndrome (LGS). Subjects will be enrolled at approximately 10 investigational sites in the U.S. for up to 15 weeks. Subjects will be randomly assigned to either a low dose or a high dose. The study will include a baseline period, a titration period and a maintenance period. After the maintenance period, subjects will either continue into an open-label extension study or enter the taper period with a final visit 1 week after the last dose.

Completed16 enrollment criteria

Phase III Double Blind Trial of Valproate Sodium for Prophylaxis of Post Traumatic Seizures

Post-Traumatic Seizure DisorderHead Injuries

OBJECTIVES: I. Determine whether treating head injured patients with valproate sodium will reduce the risk of developing seizures as a result of the head injury. II. Determine the safety of valproate, the appropriate dose, and the effect valproate may have on the recovery of the brain's ability to compute numbers, solve problems, remember information, and control the movement of limbs after head injury.

Completed18 enrollment criteria

Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy...

Intractable EpilepsyMalignant Glioma3 more

This phase IV trial studies the side effects and how well perampanel works in reducing seizure frequency in patients with high-grade glioma and focal epilepsy. Perampanel is a drug used to treat seizures. Giving perampanel together with other anti-seizure drugs may work better in reducing seizure frequency in patients with high-grade glioma and focal epilepsy compared to alternate anti-seizure drugs alone.

Terminated19 enrollment criteria

Clinical Trial for Zebinix (Eslicarbazepine Acetate) in Healthy Korean and Caucasian Adult

Partial-onset Seizures With or Without Secondary Generalisation

A dose randomized, double-blind, placebo controlled, single and multiple dosing, dose-escalation phase I clinical trial to investigate the safety, tolerability and pharmacokinetic characteristics of Zebinix (Eslicarbazepine acetate) after oral administration in healthy Korean and Caucasian adult subjects

Completed21 enrollment criteria

Inflammatory Biomarkers in Psychogenic Non-epileptic Seizure

Localization-Related (Focal) (Partial) Idiopathic Epilepsy and Epileptic Syndromes With Seizures of Localized OnsetTRAIL: Tumor Necrosis Factor Related Apoptosis Inducing Ligand MCP-21 more

Evaluation of the role of TRAIL and MCP-2 in differentiation between epileptic seizure and psychogenic non-epileptic seizure. Possible role to predict the prognosis of patients with epileptic seizure.

Not yet recruiting3 enrollment criteria

A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure...

Focal Onset SeizureFocal Onset Epilepsy

This study will evaluate the safety, pharmacokinetics, and efficacy of three different doses of NBI-921352 versus placebo in adults with focal onset seizures

Completed20 enrollment criteria
1...363738...78

Need Help? Contact our team!


We'll reach out to this number within 24 hrs